On June 14 and 15, 2022, the Department of Justice Antitrust Division (“DOJ”) and the Federal Trade Commission (“FTC”) hosted a virtual workshop to discuss antitrust analysis of pharmaceutical mergers and anticipated focal...more
On Tuesday, May 11, 2021, an international coalition of competition enforcement agencies including the Federal Trade Commission, the U.S. Department of Justice’s Antitrust Division, Offices of State Attorneys General,...more
In a recent decision in In Re Humira (Adalimumab) Antitrust Litigation, No. 19-cv-1873, Judge Shah of the Northern District of Illinois dismissed a consolidated class action complaint filed by U.S. purchasers of AbbVie Inc.’s...more
6/22/2020
/ Anti-Competitive ,
Antitrust Injuries ,
Antitrust Litigation ,
Biopharmaceutical ,
Biosimilars ,
BPCIA ,
Class Action ,
Monopolization ,
Noerr-Pennington Doctrine ,
Patent Dance ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Sherman Act ,
USPTO